Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Skysona
Pharma
FDA considers 'regulatory action' for bluebird's Skysona
The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s Skysona and is considering regulatory action.
Kevin Dunleavy
Dec 2, 2024 11:22am
Bluebird down 18% with slow uptake of SCD gene therapy Lyfgenia
Aug 14, 2024 12:07pm
HHS provides unfavorable opinion on bluebird's fertility program
Jul 22, 2024 5:26pm
With 64 centers activated, bluebird is ready to grow Lyfgenia
May 9, 2024 1:40pm
Bluebird discusses Lyfgenia launch details and accounting errors
Mar 26, 2024 10:49am
Bluebird secures $175M loan from Hercules Capital
Mar 18, 2024 11:49am
